Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...
DBI posted a 54% total return in 2025 with just one red month. Here's why its unique business model provides unmatched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback